tetravalent influenza virus split vaccine

**Tetravalent influenza virus split vaccine** is a sponsor-specific, nonadjuvanted quadrivalent inactivated split-virion influenza vaccine listed in the pipeline of Chongqing Institute of Biological Products. It is designed to prevent influenza caused by two influenza A subtypes, H1N1 and H3N2, and two influenza B lineages, Victoria and Yamagata. The egg-derived vaccine is produced from cultivated influenza viruses that are purified, chemically inactivated, and split to yield viral antigens, including hemagglutinin and neuraminidase. Vaccination is intended to elicit strain-specific humoral immune responses, including neutralizing antibodies, against the included influenza strains. The described asset is distinct from the sponsor's separate ZFA02-adjuvanted quadrivalent influenza split-vaccine program. ([en.zhifeishengwu.com](https://en.zhifeishengwu.com/produce/zycp/))

Brand names

Feimuxi

Other names

tetravalent influenza virus split vaccineQuadrivalent Influenza Vaccine (Split Virion)